Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBT Margin (2023 - 2025)

CG Oncology's EBT Margin history spans 3 years, with the latest figure at 1776.74% for Q4 2025.

  • For Q4 2025, EBT Margin rose 519782.0% year-over-year to 1776.74%; the TTM value through Dec 2025 reached 3981.26%, up 374850.0%, while the annual FY2025 figure was 3981.26%, 374850.0% up from the prior year.
  • EBT Margin reached 1776.74% in Q4 2025 per CGON's latest filing, up from 2623.53% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1776.74% in Q4 2025 to a low of 1655100.0% in Q4 2023.
  • Average EBT Margin over 3 years is 193556.09%, with a median of 12005.3% recorded in 2024.
  • Peak YoY movement for EBT Margin: surged 164812544bps in 2024, then crashed -6306403bps in 2025.
  • A 3-year view of EBT Margin shows it stood at 1655100.0% in 2023, then skyrocketed by 100bps to 6974.56% in 2024, then surged by 75bps to 1776.74% in 2025.
  • Per Business Quant, the three most recent readings for CGON's EBT Margin are 1776.74% (Q4 2025), 2623.53% (Q3 2025), and 66263.46% (Q1 2025).